Diagnostic utility of LunX mRNA in peripheral blood and pleural fluid in patients with primary non-small cell lung cancer.
Diagnostic utility of LunX mRNA in peripheral blood and pleural fluid in patients with primary non-small cell lung cancer.
复制标题
DOI：
10.1186/1471-2407-8-156
复制
发表时间：
2008-05-31
期刊：
影响因子：
3.8
通讯作者：
Wei H
中科院分区：
文献类型：
--
作者：
Cheng M;Chen Y;Yu X;Tian Z;Wei H
由于缺乏临床上有用的诊断标志物，肺癌的进展受到阻碍。本研究的目的是提供一个详细的评估肺癌肿瘤标志物的分子异常的指示，并评估其在非小细胞肺癌（NSCLC）患者的诊断效用。采用实时荧光定量RT-PCR方法检测NSCLC患者外周血和胸水中LunX、CK 19、CEA、VEGF-C和hnRNP A2/B1 mRNA水平，并与其他上皮癌（食管癌、乳腺癌）、良性肺病（肺炎、结核性胸膜炎）和健康志愿者进行比较。75.0%（33/44）的NSCLC患者外周血中检测到LunX mRNA，而其他上皮癌（0/28）、良性肺病（0/10）和健康志愿者（0/15）均未检测到LunX mRNA。相比之下，所有其他遗传标记在患有NSCLC、其他上皮癌或良性肺部疾病的患者以及健康志愿者中检测到。外周血LunX mRNA表达水平和阳性率与NSCLC病理分期相关（P < 0.001和P = 0.010）。LunX mRNA在92.9%（13/14）的恶性胸液中表达，是唯一在良恶性胸液中表达差异有统计学意义（P < 0.001）的标志物。此外，NSCLC患者外周血中LunX mRNA的表达在临床治疗后不久下降（P = 0.005）。在几种常用的遗传标记物中，LunX mRNA是肺癌最特异的基因标记物，当在NSCLC患者的外周血和胸腔液中测量时具有潜在的诊断效用。
Progress in lung cancer is hampered by the lack of clinically useful diagnostic markers. The goal of this study was to provide a detailed evaluation of lung cancer tumor markers indicative of molecular abnormalities and to assess their diagnostic utility in non-small cell lung cancer (NSCLC) patients. Quantitative real-time RT-PCR was used to determine LunX, CK19, CEA, VEGF-C and hnRNP A2/B1 mRNA levels in peripheral blood and pleural fluid from NSCLC patients, compared with those from patients with other epithelial cancer (esophagus cancer and breast cancer), benign lung disease (pneumonia and tuberculo pleurisy) and from healthy volunteers. In peripheral blood LunX mRNA was detectable in 75.0% (33/44) of patients with NSCLC, but not in patients with other epithelial cancer (0/28), benign lung disease (0/10) or in healthy volunteers (0/15). In contrast, all other genetic markers were detected in patients with either NSCLC, other epithelia cancer or benign lung disease, and in healthy volunteers. The expression level and positive rate of LunX mRNA in peripheral blood correlated with the pathologic stage of NSCLC (P < 0.001 and P = 0.010 respectively). Furthermore, LunX mRNA was detected in 92.9% (13/14) of malignant pleural fluid samples and was the only marker whose expression level was significantly different between malignant and benign pleural fluid (P < 0.001). Additionally, expression of LunX mRNA in the peripheral blood of NSCLC patients decreased shortly after clinical treatment (P = 0.005). Of several commonly used genetic markers, LunX mRNA is the most specific gene marker for lung cancer and has potential diagnostic utility when measured in the peripheral blood and pleural fluid of NSCLC patients.
登录
查看更多内容
影响因子：
6.4
作者：
Matsunaga, H;Hangai, N;Mitsuhashi, M
通讯作者：
Mitsuhashi, M
影响因子：
4.8
作者：
Li, YY;Dong, XY;Chen, WF
通讯作者：
Chen, WF
影响因子：
4.1
作者：
Mitas, M;Hoover, L;Gillanders, WE
通讯作者：
Gillanders, WE
影响因子：
9.6
作者：
Lee, JH;Chang, JH
通讯作者：
Chang, JH
影响因子：
45.3
作者：
Castaldo, G;Tomaiuolo, R;Salvatore, F
通讯作者：
Salvatore, F